Home › NDC Lookup › RxCUI directory › RxCUI 1048336

Hyoscyamine sulfate 0.12 MG / methenamine 81 MG / methylene blue 10.8 MG / phenyl salicyla... — RxCUI 1048336

RxNorm drug concept · Semantic clinical drug
RxCUI 1048336 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1048336
Official nameHyoscyamine sulfate 0.12 MG / methenamine 81 MG / methylene blue 10.8 MG / phenyl salicylate 32.4 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Methenamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That's a great question. Methenamine isn't used to clear an active infection — it's used to prevent another one from taking hold. Once your other antibiotic has done that job, meth...
  • Why do I need to take methenamine if my infection is already gone?
  • Yes, it actually does. Methenamine only converts into its active antibacterial form in acidic urine. Foods and medications that make your urine more alkaline — less acidic — can re...
  • Does it matter what I eat or drink while I'm on this medication?
📖 Read our full Methenamine guide →

🕸️ Concept Web — How Hyoscyamine sulfate 0.12 MG / methenamine 81 MG... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Hyoscyamine sulfate 0.12 MG / methenamine 81 MG / methylene blue 10.8 MG / phenyl salicylate 32.4 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet RxCUI 1048336

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 7

    The active substance itself — no strength, form, or brand attached yet.

    • Hyoscyamine 153970
    • Methenamine 6832
    • Methylene blue 6878
    • Phenyl salicylate 36122
    • Sodium phosphate, monobasic 235496
    • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic 1007374
    • Hyoscyamine sulfate 1225
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Urelle 353527
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet 562663
    • Hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet 2649347
    • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Product 1164652
    • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Pill 1164653
    • Hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Product 2659194
    • Hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Pill 2659588
    • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle] 895937
    • Hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle] 2655814
    • +5 more in this family
  4. Clinical & branded drugs 7

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 23 of 28 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Hyoscyamine sulfate 0.12 MG SCDC · 1037233
  • Methenamine 81 MG SCDC · 353393
  • Methylene blue 10.8 MG SCDC · 384913
  • Phenyl salicylate 32.4 MG SCDC · 353394
  • Sodium phosphate, monobasic 40.8 MG SCDC · 384927
  • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet SCDF · 562663
  • Hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet SCDFP · 2649347
  • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Product SCDG · 1164652
  • Hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Pill SCDG · 1164653
  • Hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Product SCDGP · 2659194

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1048336 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00037-6321-90 90 TABLET in 1 BOTTLE (0037-6321-90) URELLE Viatris Specialty LLC 2015-01-12
Observed labelers: Viatris Specialty LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$9.4315
Range $9.4315–$9.4315 · middle 50% $9.4315–$9.4315 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.